Holding company Symphony Technology Group (STG) has sold its biopharma and consumer health research and analytics firm AlphaImpactRx to IMS Health. Terms of the deal were not disclosed.
AlphaImpactRx was founded by STG in 2011 through the combination of physician primary market research platforms ImpactRx, TargetRx and AlphaDetail. The company briefly operated as a subsidiary of STG portfolio company Symphony Health Solutions, created after the firm acquired Source Analytics, but was then spun out as a separate company at the end of 2014.
STG's current healthcare portfolio includes syndicated data and analytics provider Symphony Health Solutions; patient experience optimization and solutions company SPH Analytics; insight and solutions firm Evidera; NHS IT systems supplier System C; and French electronic patient records provider Maincare Solutions. J.T. Treadwell, Managing Director of STG, says the sale works well for all sides, while his firm continues to work with its remaining portfolio companies.
AlphaImpactRx's capabilities and technologies will be integrated into IMS Health. AlphaImpactRx CEO John Ouren (pictured) comments: 'IMS Health is a great home for our business and our people. The company has a broad global platform across many different areas in healthcare and technology, and we believe those additional capabilities will enable us to better serve our clients and grow our platform'.
Web sites: www.symphonytg.com , www.alphaimpactrx.com and www.imshealth.com .
All articles 2006-21 written and edited by Mel Crowther and/or Nick Thomas unless otherwise stated.